HOOKIPA Pharma Company Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.
The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer.
HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.
The company was incorporated in 2011 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Malte Peters |
Contact Details
Address: 350 Fifth Avenue New York, New York New York United States | |
| Phone | 431 890 6360 |
Stock Details
| Ticker Symbol | HOOK |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US43906K1007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Malte Peters M.D. | Chief Executive Officer, President and Director |
| Mary Theresa Coelho M.B.A. | Executive Vice President, Chief Financial Officer and Director |
| Dr. Daniel D. Pinschewer M.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Mark Winderlich Ph.D. | Chief Research and Development Officer |